With approximately 1.3 million infections and more than 50,000 deaths every year, leishmaniasis is an important infectious disease that has an endemic status in the majority of Latin America, countries of the Mediterranean basin, the Middle East, and certain areas of Africa and Asia [1] [2] [3] [4] [5] [6]. The protozoan parasite Leishmania, the causative agent of leishmaniasis, is transmitted to the human host by the sand fly vector from a number of animal hosts (or other human hosts that are already infected, in which case the term anthroponotic leishmaniasis is used) [1] [3]. Mucocutaneous leishmaniasis is one of the three clinical forms (in addition to visceral and cutaneous) of this parasitic infection, distinguished by the onset of lesions on the skin and on mucous membranes as well [1] [2] [3] [4] [7] [8]. Certain Leishmania species (L. braziliensis, L. major, L. panamensis, L. guyanensis, L. infantum, and L. donovani) are known for their propensity to produce mucocutaneous forms that start with the development of an erythematous papule at the site of the sand fly bite [1] [3]. The face and the extremities are usually the locations of the initial lesion, which can appear weeks or even years after the bite [1] [3]. Over time, the papule increases in size and eventually breaks, leading to the formation of a painless, well-demarcated ulcer [1] [3]. Spontaneous resolution within a few months is seen in the majority of cases, but new lesions might appear at various sites on the body [1] [3]. The distinguishing feature of mucocutaneous leishmaniasis is the mucosal involvement, predominantly in the oral cavity and the nasopharynx [2] [8].

A thorough clinical approach is necessary in order to make the diagnosis of mucocutaneous leishmaniasis. A meticulously obtained patient history should be the first step, during which the physician must bear in mind the country of residence and travel to endemic areas in the past several years, whereas a history of sand fly bites might be assessed as well. A properly conducted physical examination, with an emphasis on the inspection of the skin and the oral cavity, may be even more important for identifying the lesions seen in mucocutaneous leishmaniasis. To solidify clinical suspicion, however, several microbiological tests can be employed. Scrapings from the lesions are used for microscopic smear examination or cultivation, the former being a superior method due to the longer turnaround time of cultures (up to 10 days are necessary for Leishmania to grow on standard media) [3] [4]. A histological examination of a biopsy sample (using hematoxylin-eosin staining) can be carried out, but the introduction of serological and molecular studies have greatly improved the overall rate of diagnosis [3] [4]. The Montenegro's test, comprised of inoculating Leishmania antigen into the forearm, can yield conclusive results after 72 hours [3] [4] [8]. Polymerase chain reaction (PCR), although being expensive and more sophisticated compared to the previously mentioned methods, should be implemented whenever possible, primarily because of its very high sensitivity/specificity rates [3] [4] [9].

Treatment of Mucocutaneous Leishmaniasis usually involves antiparasitic medications. The most commonly used drugs are pentavalent antimonials, such as sodium stibogluconate or meglumine antimoniate. Amphotericin B and miltefosine are alternative treatments. The choice of treatment depends on the severity of the disease, the specific Leishmania species involved, and the patient's overall health.

The prognosis for MCL varies. With timely and appropriate treatment, many patients can achieve a cure, although some may experience residual scarring or disfigurement. Without treatment, the disease can lead to severe complications, including significant tissue destruction and secondary infections, which can be life-threatening.

Mucocutaneous Leishmaniasis is caused by specific species of the Leishmania parasite, primarily Leishmania braziliensis. These parasites are transmitted to humans through the bites of infected female phlebotomine sandflies. The disease is more common in certain geographic regions, particularly in parts of Central and South America.

MCL is endemic in rural and forested areas of Central and South America, including countries like Brazil, Peru, and Bolivia. It affects both men and women, although occupational exposure in rural settings may lead to a higher incidence in males. The disease is associated with poverty, deforestation, and rural living conditions.

The pathophysiology of MCL involves the initial infection of skin macrophages by Leishmania parasites. Over time, the parasites can disseminate to mucosal tissues, where they trigger an inflammatory response. This immune response, while attempting to control the infection, can lead to tissue damage and the characteristic mucosal lesions of MCL.

Preventing Mucocutaneous Leishmaniasis involves reducing exposure to sandfly bites. This can be achieved through the use of insect repellent, protective clothing, and bed nets. Environmental measures, such as controlling sandfly populations and improving housing conditions, can also help reduce the risk of infection.

Mucocutaneous Leishmaniasis is a serious parasitic disease that affects the skin and mucous membranes. It is caused by Leishmania parasites transmitted by sandflies. Early diagnosis and treatment are crucial to prevent severe complications. Preventive measures focus on reducing exposure to sandfly bites.

If you suspect you have Mucocutaneous Leishmaniasis, it is important to seek medical attention. The disease starts with skin lesions and can progress to affect the nose and mouth. Treatment is available and effective, especially when started early. Protecting yourself from sandfly bites is key to prevention.

1. Palumbo E. Treatment strategies for mucocutaneous leishmaniasis. J Glob Infect Dis. 2010;2(2):147-150.
2. Elmahallawy EK, Sampedro Martinez A, Rodriguez-Granger J, et al. Diagnosis of leishmaniasis. J Infect Dev Ctries. 2014;8(8):961-972.
3. Masmoudi A, Hariz W, Marrekchi S, Amouri M, Turki H. Old World cutaneous leishmaniasis: diagnosis and treatment. J Dermatol Case Rep. 2013;7(2):31-41.
4. Davies CR, Kaye P, Croft SL, Sundar S. Leishmaniasis: new approaches to disease control. BMJ. 2003;326(7385):377-382.
5. World Health Organization. The world health report. Geneva: WHO; 2002. Annex 3: Burden of disease in DALYs by cause, sex and mortality stratum in WHO regions, estimates for 2001; pp. 192–197.www.who.int/whr/2002/whr2002_annex3.pdf
6. Alvar J, Vélez ID, Bern C, et al. Leishmaniasis worldwide and global estimates of its incidence. PLoS One. 2012;7:e35671.
7. Savoia D. Recent updates and perspectives on leishmaniasis. J Infect Dev Ctries. 2015;9(6):588-596.
8. Diniz JL, Costa MO, Gonçalves DU. Mucocutaneous Leishmaniasis: clinical markers in presumptive diagnosis. Braz J Otorhinolaryngol. 2011;77(3):380-384.
9. Lemrani M, Hamdi S, Laamrani A, Hassar M. PCR detection of Leishmania in skin biopsies. J Infect Dev Ctries. 2009;3(2):115-122.